The startup develops the RP-323 compound, a gene repair therapy that targets damaged or mutated cells caused by cancer and viral infections. By effectively crossing the blood-brain barrier, this therapy enables medical research companies to treat the underlying causes of diseases, facilitating the body's natural repair processes.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many life-threatening diseases, including cancers, neurological disorders, and inflammatory conditions, are driven by damaged or malfunctioning cells that disrupt normal physiological processes. Current treatments often address the symptoms of these diseases without fully repairing the underlying cellular damage or restoring proper function.
Solution
PhorMed is a clinical-stage biopharmaceutical company developing RP-323, a cell repair therapy and immunotherapy designed to target the underlying mechanisms of disease. RP-323 is a synthesized molecule derived from Croton tiglium L. oil, engineered to modulate cellular processes at the DNA level, promoting normal cell proliferation, differentiation, and apoptosis. By targeting multiple cell lines, RP-323 aims to repair damaged cells, reduce inflammation, and enhance the body's natural defense system. PhorMed is currently advancing RP-323 through clinical trials for Acute Myeloid Leukemia (AML), Hodgkin’s Lymphoma (HL), and Acute Respiratory Distress Syndrome (ARDS), with preclinical studies underway for Parkinson’s Disease (PD).
Target Audience
PhorMed's primary target audience includes medical professionals and patients seeking innovative treatments for cancers such as Acute Myeloid Leukemia and Hodgkin’s Lymphoma, neurological disorders like Parkinson’s Disease, and inflammatory conditions such as Acute Respiratory Distress Syndrome.
Features
- Targets multiple cell lines to repair damaged cellular processes at the DNA level
- Modulates phosphorylation to control DNA expression and enzyme production for normal cell function
- Enhances the immune system through cytokine induction
- Designed to cross the blood-brain barrier for neurological applications
- Addresses the underlying mechanisms of disease in oncology, neurology, and inflammatory conditions
- Currently in Phase II clinical trials for AML, HL, and ARDS
- Preclinical studies ongoing for Parkinson’s Disease